The results of the study showed that the S100B concentration in serum from patients with T2DM, from whom blood was collected before COVID-19, was detectable (≥7.8 pg/mL) in 7 out of 59 patients with T2DM, representing 11.9% of the entire group. The gene discussed is S100B; the disease is COVID-19.